Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Detrane

Gastroenterology Fredericksburg, VA Medical Doctor

NPI 1265516686 CMS profile 284532

1031 Care Way, Fredericksburg, VA 22401

Open in the dashboard

General payments

$8,743

498 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Detrane of Fredericksburg, VA is reported in the CMS Open Payments database as having received $8,743 across 498 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,812 86
2024 General $1,655 90
2023 General $1,321 84
2022 General $1,519 93
2021 General $953 55
2020 General $416 26
2019 General $1,067 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Detrane
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Frank Detrane were reported at $1,812. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Frank Detrane Gastroenterology median Middle half National median
2019 $1,067 $417 $126–$1,100 $163
2020 $416 $224 $74–$624 $114
2021 $953 $352 $106–$1,054 $132
2022 $1,519 $448 $129–$1,270 $149
2023 $1,321 $533 $150–$1,390 $160
2024 $1,655 $605 $160–$1,606 $164
2025 $1,812 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,493 169 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,290 84 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $921 48 payments
  4. Janssen Biotech, Inc. $717 30 payments
  5. QOL Medical, LLC $460 26 payments
  6. Ironwood Pharmaceuticals, Inc $428 23 payments
  7. Genzyme Corporation $397 16 payments
  8. Pfizer Inc. $338 16 payments
  9. Gilead Sciences, Inc. $231 12 payments
  10. Daiichi Sankyo Inc. $188 9 payments
  11. Other $1,279 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,743 498 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,037 53 payments
  2. CREON $844 54 payments
  3. ENTYVIO $824 56 payments
  4. LINZESS $634 40 payments
  5. RINVOQ $622 41 payments
  6. TREMFYA $618 24 payments
  7. STELARA $612 25 payments
  8. HUMIRA $594 35 payments
  9. SIMPONI $525 20 payments
  10. SIMPONI ARIA $514 19 payments
  11. Other $4,571 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,465

Median for Gastroenterology: 569

Drug cost

$858,741

Median for Gastroenterology: $104,976

Branded share of claims

27%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 11 $313,934
Creon Lipase/Protease/Amylase Brand 70 $292,911
Linzess Linaclotide Brand 134 $105,004
Xifaxan Rifaximin Brand 15 $48,273
Ibsrela Tenapanor Hcl Brand 11 $29,546
Mesalamine Generic 32 $26,528
Budesonide Ec Budesonide Brand 11 $10,153
Omeprazole Generic 466 $6,988
Esomeprazole Magnesium Generic 84 $3,824
Pantoprazole Sodium Generic 237 $3,680

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$215,465

Medicare's payments for the services billed

Medicare patients

650

Average age 74

Services billed

5,957

395 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 34%
Diabetes 26%
Cancer 19%
Chronic kidney disease 18%
Atrial fibrillation 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $213
$213 — —
LINZESS
  • AbbVie, Inc. $125
  • Ironwood Pharmaceuticals, Inc $74
$199 134 —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $189
$189 15 —
CREON
  • AbbVie, Inc. $123
$123 70 —
DUPIXENT
  • GENZYME CORPORATION $110
$110 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

498 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record